An analyst waxed bullish on the company's leading pipeline program.

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

U.S. representative from Austin asks Health and Human Services secretary to push for generic licensing of semaglutide ...

One of the current stars of the biotech world is Viking Therapeutics (NASDAQ: VKTX), and for good reason. The clinical-stage company is advancing to the later stages of developing a drug that, if ...

The future of oral weight loss medication looks bright. Drug manufacturer Novo Nordisk announced a new experimental ...

The shortage of popular diabetes and weight-loss drugs known as GLP-1s — and insurers’ uneven coverage of them — is putting an unprecedented supply of compounded drugs in consumers' medicine cabinets.

The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.

The actor, who first found fame on slimming club comedy Fat Friends, has not had the same success with the hugely popular weight-loss jab and has stopped taking it claiming it didn't work for him.

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...